Statements of Cash Flows (USD $)	12 Months Ended			120 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2014
Cash flows used in operating activities
Net loss for the period	$ (116,928)	$ (209,900)	$ (179,382)	$ (2,178,876)
Adjustments to reconcile net loss to cash used by operating activities
Amortization	43	196	449	6,930
Write-down of intangible assets				1,278
Write-off of equipment		823		823
Changes in operating assets and liabilities
Decrease (increase) in amounts receivable	(1,423)	40	1,496	(4,267)
Increase (decrease) in accounts payable and accrued liabilities	12,898	2,376	(800)	(12,891)
Total	(105,410)	(206,465)	(178,237)	(2,187,003)
Cash flows from investing activities
Purchase of equipment				(7,850)
Purchase of intangible assets				(1,278)
Cash acquired on the purchase of Molecular Pharmacology (USA) Limited				37,163
Total				28,035
Cash flows from (used in) financing activities
Common shares issued for cash				234,497
Increase (decrease) in due to related parties	162,795	(24,947)	105,919	2,199,088
Total	162,795	(24,947)	105,919	2,433,585
Effect of exchange rate changes on cash	(62,053)	235,886	66,215	(272,239)
Increase (decrease) in cash and cash equivalents	(4,668)	4,474	(6,103)	2,378
Cash and cash equivalents, beginning of year	7,046	2,572	8,675
Cash and cash equivalents, end of year	$ 2,378	$ 7,046	$ 2,572	$ 2,378